131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes
复制标题
DOI：
10.1097/mnm.0b013e328358d34b
复制
发表时间：
2012-12-01
影响因子：
1.5
通讯作者：
Rajendran, Joseph G.
中科院分区：
文献类型：
--
作者：
Hattori, Naoya;Gopal, Ajay K.;Rajendran, Joseph G.
目的 探讨放射性标记抗 CD20 抗体对睾丸的辐射剂量及其对男性性激素水平的影响。 材料和方法 对 67 名接受清髓性放射免疫治疗 (RIT) 的非霍奇金淋巴瘤男性患者 (54+/-11 岁) 进行测量，测量睾丸对 I-131-托西莫单抗的摄取和保留，并计算睾丸吸收剂量。 I-131-托西莫单抗。主要器官、睾丸和全身的时间-活动曲线是通过平面成像研究生成的。在一部分患者中，在治疗前和治疗后 1 年测量了男性性激素。结果 睾丸吸收剂量显示出相当大的变异性（范围 = 4.4-70.2 Gy）。治疗前总睾酮水平低于参考范围的下限，治疗后评估显示进一步降低[4.6+/-1.8 nmol/l（RIT前）与3.8+/-2.9 nmol/l（RIT后），P = 25 Gy）显示出更大的降低[4.7+/-1.6 nmol/l（RIT前）与3.3+/-2.7 nmol/l（RIT后），P
Purpose To investigate radiation doses to the testes delivered by a radiolabeled anti-CD20 antibody and its effects on male sex hormone levels.Materials and methods Testicular uptake and retention of I-131-tositumomab were measured, and testicular absorbed doses were calculated for 67 male patients (54+/-11 years of age) with non-Hodgkin's lymphoma who had undergone myeloablative radioimmunotherapy (RIT) using I-131-tositumomab. Time-activity curves for the major organs, testes, and whole body were generated from planar imaging studies. In a subset of patients, male sex hormones were measured before and 1 year after the therapy.Results The absorbed dose to the testes showed considerable variability (range = 4.4-70.2 Gy). Pretherapy levels of total testosterone were below the lower limit of the reference range, and post-therapy evaluation demonstrated further reduction [4.6+/-1.8 nmol/l (pre-RIT) vs. 3.8+/-2.9 nmol/l (post-RIT), P= 25 Gy) showed a greater reduction [4.7+/-1.6 nmol/l (pre-RIT) vs. 3.3+/-2.7 nmol/l(post-RIT), P